Keratosis Pilaris-Like Eruption During Chronic Myeloid Leukemia Treatment With Tyrosine Kinase Inhibitors: A Literature Review And Case Report On Imatinib

December 2023 in “ Journal of clinical medicine ”

Francesca Ambrogio, Melita Anna Poli, Lucia Lospalluti, Teresa Lettini, Nicoletta Cassano, Gino Antonio Vena, Giuseppe Ingravallo, Gerardo Cazzato, Caterina Foti

keratosis pilaris chronic myeloid leukemia tyrosine kinase inhibitors imatinib nilotinib dasatinib scalp alopecia body hair loss follicular atrophy perifollicular fibrosis KP CML TKIs

Studysummary This study reports the case of an elderly patient with a keratosis pilaris-like skin eruption after beginning treatment with imatinib for chronic myeloid leukemia, discussing similar skin reactions to BCR-ABL inhibitors and exploring potential mechanisms behind these adverse cutaneous reactions. Our plain-language summary of this paper — not a Tressless recommendation.

The document reviews the occurrence of keratosis pilaris (KP)-like eruptions in patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs), focusing on a case involving imatinib. It highlights that such skin reactions, though rare with imatinib, are more common with second-generation TKIs like nilotinib and dasatinib. In a study of 39 CML patients, 23% developed extensive KP, 41% had scalp alopecia, and 38.5% experienced body hair loss. Histopathological examinations showed follicular atrophy and perifollicular fibrosis. The review underscores the importance of recognizing and managing these dermatological side effects in CML patients treated with TKIs.

View this study on mdpi.com →

Discuss this study in the Community →

Research cited in this study

7 / 7 results

research Nilotinib-Induced Generalized Keratosis Pilaris: Report of a Rare Case

5 citations , January 2021 in “Indian Journal of Pharmacology”

This case study reports generalized keratosis pilaris as a rare cutaneous side effect of nilotinib in a 40-year-old woman with chronic myeloid leukemia, highlighting the need for awareness among physicians.

research Nilotinib Induced Keratosis Pilaris Atrophicans

10 citations , August 2016 in “Dermatology Online Journal”

This article describes cutaneous reactions including keratosis pilaris-like eruptions in a patient on nilotinib for chronic myelogenous leukemia, emphasizing the importance of accurately classifying such eruptions.

research Nilotinib-Induced Keratosis Pilaris

19 citations , April 2016 in “Case Reports in Dermatology”

This case report highlights an instance of nilotinib-induced keratosis pilaris without alopecia or pruritus, emphasizing the need for awareness to optimize patient outcomes.

research Unique Cutaneous Reaction to Second- and Third-Generation Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

32 citations , September 2015 in “Dermatology”

This study describes a newly recognized skin reaction associated with dasatinib, nilotinib, and ponatinib, marked by a lichenoid exanthem with severe pruritus that may necessitate discontinuation of therapy.

Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia

research Adverse Cutaneous Reactions to the New Second-Generation Tyrosine Kinase Inhibitors (Dasatinib, Nilotinib) in Chronic Myeloid Leukemia

25 citations , November 2013 in “Journal of the American Academy of Dermatology”

This study observed that 71% of chronic myeloid leukemia patients treated with second-generation tyrosine kinase inhibitors experienced adverse cutaneous reactions, which were generally less severe than those caused by imatinib.

research Correction: RASopathic Skin Eruptions During Vemurafenib Therapy

4 citations , October 2013 in “PLoS ONE”

This study found that Vemurafenib led to a broad range of cutaneous side effects in nearly all patients with advanced melanoma, highlighting the need for regular dermatologic management and UV protection.

research RASopathic Skin Eruptions During Vemurafenib Therapy

82 citations , March 2013 in “PLoS ONE”

In this study, vemurafenib was associated with a wide range of cutaneous side effects in patients with advanced melanoma, including photosensitivity and various skin and hair changes, necessitating regular dermatological management.